Pursuing Novel Ideas
Pioneering Innovative Therapies
Lipella Pharmaceuticals Inc is a privately held development-stage biotechnology company dedicated to improve patient
care by developing novel products which focus on trans-mucosal therapy, delivering local treatments directly to their site of action. Our therapeutic focus currently
include Interstitial Cystitis / Painful Bladder Syndrome (IC/PBS), Overactive Bladder (OAB), and Superficial Bladder Cancer.
Lipella believes our theraputic focus represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of our core products.
Lipella applies a familiar technology, liposomes, to a novel target, the mucosal barrier. Lipella’s lead product is the first liposomal therapy for bladder irritation. Lipella’s liposomal intravesical instillation is already gaining broad appeal, offering a real solution to many people who suffer from IC and OAB who otherwise have no adequate treatment options.